It is a link for moving within the page.

  1. HOME
  2. About Otsuka
  3. News Releases
  4. 2021
  5. Busulfex Injection 60mg Approved in Japan for Once-daily Administration in Pediatric Patients

August 25, 2021

Otsuka Pharmaceutical Co., Ltd.

Pharmaceuticals

Busulfex Injection 60mg Approved in Japan for Once-daily Administration in Pediatric Patients

Otsuka Pharmaceutical Co., Ltd. today announces it has received regulatory approval in Japan for a once-daily form in pediatric patients of Busulfex® Injection 60 mg (generic name is busulfan). Busulfex is a conditioning regimen administered via intravenous drip to patients prior to undergoing hematopoietic stem cell transplantation.

Approval in Japan reflects the once-daily usage pattern for Busulfex in pediatric patients and adults in other countries around the world.


Information in this news release was current as of the original release date.

Latest Pharmaceutical Business related News Releases

Most Recent Releases